Member Info for Hurst10

150-5 opening, with NEJM and Lancet etc picking up the board appointments and how significant and well known they are!
Moderna will love it

From IG:
Three stocks to watch :
https://www.ig.com/uk/news-and-trade-ideas/uk-stock-preview--rolls-royce--shell--avacta-210906

Avacta have stated they have manufacturing capacity in place for millions per month, does this indicate demand is larger than + 10 mill per month.
Once Avacta have U.K. /EUA OTC approval, which should be any day, with the Schools,Uni’s etc starting, well it will be a busy quarter, something the company will address at Results?
Friday rally in the stock coming up shortly.

Excellent article in Drug Discovery World published overnight ref AVA6000 and the potential market.

https://www.ddw-online.com/building-a-pipeline-of-clinically-differentiated-cancer-therapies-13092-202109/

Will be an exciting month ahead for Avacta, with results out etc.

Just out in the New England Journal of Medicine.:
Conclusion is very much the need for further testing!

Subject: Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce | NEJM
?Study mentions ? intensive testing strategies ? due to the emergence of Delta virus.
https://www.nejm.org/doi/full/10.1056/NEJMc2112981

Buy side in size

3 month breakout, next 150

Could be US inst. buyers, very often these trades are printed NY opening hours

Blocks of 100,000 going through on the buy side

More testing!
https://www.telegraph.co.uk/news/2021/08/30/schools-will-need-reintroduce-tougher-covid-measures-weeks-warn/

Worth picking up more at these levels, very good read across from Roche?s $3 bill gene therapy JV with Shape Therapeutics.
Avacta?s JV AffyXell with Daewoong!

New Covid Variant Found in South Africa Has Concerning Mutations

Wait the schools start.
Demand for OTC testing will be substantial.
Scientists Warn Covid Set to Grow Exponentially in U.K. Schools
https://www.bloomberg.com/news/articles/2021-08-27/scientists-warn-covid-set-to-grow-exponentially-in-u-k-schools

Coming into US hours, US OTC Rapid Antigen flow tests are back making headlines.
With UK about to approve at home use for high quality Rapid Flow Antigen Tests,such as Antigen,we will see the same response from Schools, Uni’s, Offices,Airline industry etc, Avacta have manufacturing capacity standing by and are able to expand further and off course we have the AVA6000 phase one trials and number of patients progressing very quickly.
“ At-home COVID-19 tests are flying off the shelves with COVID-19 resurgence
Coronavirus Home Test (COVID-19)
Circle Creative Studio/E+ via Getty Images
Some manufacturers of at-home COVID-19 tests are experiencing a surge in demand amid a rise in COVID-19 cases across the U.S.
Abbott Laboratories (NYSE:ABT), the developer of the BinaxNOW rapid-antigen test, expects the supply shortages to last over the next few weeks as the company ramps up production after a lack of demand prompted the management to curtail production.
“While there will be some supply constraints over the coming weeks as we ramp back up—we are putting resources from all over the company to help meet this unprecedented demand,” The Wall Street Journal reported quoting a company spokesperson. “It’s difficult to scale up on a dime, but we’re doing so again, just as we did last year.”
Meanwhile, amid questions over the availability of its at-home test, Quidel (NASDAQ:QDEL) said that the company has engaged retailers to boost stocks in response to elevated demand.
At-home molecular test for COVID-19 made by Lucira Health (NASDAQ:LHDX) is also out-of-stock on the company’s website, according to The Journal. The company is taking steps to increase production, a spokesman said.
In addition to a surge in cases, the return of office workers and students into classrooms, the evidence of COVID-19 transmission through vaccinated people, and newly implemented test mandates have contributed to the uptick in demand.
In the U.S., new COVID-19 infections have climbed to the highest level since January with an average of 152,000 cases per day over the past week, CNBC reported citing data from Johns Hopkins University.”

Yep,
150,000 bought at 140, post print, official closing price 140p , stock up 25%
170-5 before a long week end

With additional manufacturing capacity getting ready and the company about to receive Home use approval and the company being highlighted in the US, with Abbott labs and Quidel completely short of capacity in the Rapid Antigen lateral flow tests and with a higher accuracy and even more interesting, so far no bad news from the AVA6000 tests, ie. none of the usual side effects from the Chemo / Doxorubicin and enhanced as well, we should see more buyers stepping in, from the US and it will not be long before one of the majors wants “ to talk “,
Up front payment and future milestone payments with ref to AVA6000 phase one

Do we have the original Innova emergency deadline announcement ?

COVID-19 Delta variant cases rise 91% among fully vaccinated in Los Angeles County - CDC
According to the latest update by the U.S. Centers for Disease Control and Prevention (CDC), some 25% of COVID-19 infections among Los Angeles County residents occurred in fully vaccinated people from May through July 25.
Among fully vaccinated persons on July 25, 55.2% had received the Pfizer (NYSE:PFE) - BioNTech (NASDAQ:BNTX) vaccine, 28.0% received Moderna (NASDAQ:MRNA) jab, and 16.8% had received Johnson & Johnson's (NYSE:JNJ) shot.
The new data involved 43,127 reported infections among Los Angeles County residents aged ?16 years.
Of them, 10,895, or 25.3%, occurred in fully vaccinated persons; 1,431, or 3.3%, were in partially vaccinated persons, and 30,801, or 71.4%, were in unvaccinated individuals.
During May 1–July 25, the percentages of Delta variant infections estimated from 6,752 samples increased from 8.6% to 91.2% in fully vaccinated persons, from 0% to 88.1% in partially vaccinated persons, and from 8.2% to 87.1% in unvaccinated persons.
However, vaccines did protect individuals from more severe cases.
According to the study, much lower percentages of fully vaccinated persons were hospitalized (3.2%), admitted to ICU (0.5%), and required mechanical ventilation (0.2%) compared with partially vaccinated persons (6.2%, 1.0%, and 0.3%, respectively) and unvaccinated persons (7.6%, 1.5%, and 0.5%, respectively).
In July, when the Delta variant was predominant, cycle threshold values were similar for unvaccinated, partially vaccinated, and vaccinated persons.
In addition to the LA County data, the CDC released an update on the HEROES-RECOVER cohort study among healthcare workers that showed a significant drop in vaccine effectiveness among vaccinated frontline workers in eight states.
Vaccine efficacy during the Delta predominant period fell to 66% from 91% in 4,217 participants before the dominance of the SARS-CoV-2 Delta variant.
Recently, CDC reported that unvaccinated individuals are 29X more likely to get hospitalized with COVID-19

Delta virus cases up 700% week on Week since June, huge shortage of test equipment.
Europe And Asia next Will happen in U.K. and EU:
Now, with the delta variant surging—and as parents, teachers and students prepare to return to the classroom or workplace, some for the first time in more than a year—demand for those fast-acting diagnostics is on the rise again. And Abbott's brand is running scarce.
To rev its production back up to speed, Abbott now aims to rehire hundreds of workers—however, the company told the NYT that may take time, and test supplies will be constrained for the coming weeks. Currently, Abbott's career site lists production team openings on day and night shifts, with offers for $2,000 sign-on bonuses.

The kind of test you will have, will be tests done under professional supervision.
That would mean school classes with teacher, Universities with supervision, airport lounges with check in tests supervision, large organisations with dedicated supervisors, hospitals, nursing homes etc, this will facilitate approved individuals supervising identities such as above and being able to “ fast track “ such an operation and off course eliminate any “ false “ testing. The market as we know is enormous and with PCR tests taking too long and continue to have issues with telling the difference between the upcoming flu variant and the Covid variant, we will experience a surge in demand for quality Covid Rapid antigen flow tests with accurate reading, UK manufactured,UK made and UK developed.
Test results in less than 20 min.
Quidel and Abbott labs are facing huge delivery problems as the Delta variant cases have 7 doubled week on week recently and with Asia continue to experience a rise in cases.
With the UK and EUA approval and non professional use approval shortly to be announced, followed by FDA approval, the statement from the CEO in his previous Q&A session,that a capacity of 30mill per month with additional capacity will not be far off.
With AVA6000 trials having gone, the current share price leaves significant upside, to put it mildly.